[ad_1] CHICAGO – Dapagliflozin (Farxiga / Forxiga, AstraZeneca) showed a significant decrease in the rate of adverse cardiac events (MACE) but significantly reduced hospitalization for heart failure in the DECLARE-TIMI 58 trial …
Read More »Dapagliflozin Heart Failure Cuts in Diabetes
